Henry Schein One Launches Image Verify to Improve Claims Accuracy
Henry Schein One Launches Image Verify, Another Transformative Step Towards Achieving the Cleanest Claims in the Industry Henry Schein One, the market leader in dental practice management systems, today announced…
Iterative Health Highlights Faster Trial Execution with ECCO 2026 Data
ECCO 2026 Data Validate Iterative Health’s Site Network Model for Faster, More Consistent Trial Execution Iterative Health, a healthcare technology and services company powering the acceleration of clinical research, today…
New CRC Findings from Brenus Pharma Unveiled at AACR Immuno-Oncology 2026
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 2026 Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the…
WELLTRUST Debuts to Advance AI-Driven Patient Identification in Clinical Research
WELL Health and HEALWELL AI Launch WELLTRUST to Empower Patients and Accelerate AI Powered Ethical Patient Identification for Clinical Research WELL Health Technologies Corp. a technology-enabled healthcare company operating outpatient…
Shufti Establishes a New Standard for VideoIdent Solutions in the DACH Region
Shufti Sets a New Benchmark for VideoIdent in the DACH Market Shufti, a global identity verification and compliance technology provider announced the expansion of its VideoIdent solution across Germany, Austria, and Switzerland…
Merck and Mayo Clinic Partner to Advance AI-Driven Drug Discovery and Precision Medicine
Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine Merck known as MSD outside of the U.S. and Canada, and Mayo Clinic,…
ENHERTU® Variation Application Accepted in EU for Post-Neoadjuvant Use in Early HER2-Positive Breast Cancer
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer The European Medicines Agency (EMA) has validated the Type II Variation…
Affinia Therapeutics Receives EMA Orphan Designation for Gene Therapy AFTX-201 in BAG3 Cardiomyopathy
Affinia Therapeutics Receives European Medicines Agency Orphan Drug Designation for AFTX-201 in BAG3-Associated Dilated Cardiomyopathy (DCM) Affinia Therapeutics an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class…
ChartCheck Adaptive Deployment Expands Across Australia with Icon Group After FDA 510(k) Clearance
Icon Group Deploys ChartCheck Adaptive Across Australia as Radformation Secures USFDA 510(k) Clearance Radformation, a leading provider of intelligent automation solutions for radiation oncology, and Icon Group (Icon), a leading global integrated…
Spruce Biosciences Advances TA-ERT Program Following Constructive Type B Discussions with U.S. FDA
Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) Spruce Biosciences, Inc. a late-stage biopharmaceutical company focused on…
KalVista’s EKTERLY® Added as First-Line Treatment for Patients Aged 12+ in Pediatric HAE Guideline
KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline KalVista Pharmaceuticals, Inc. today announced that the newly published…
Korsana Biosciences Launches with $175 Million to Develop Innovative Neurodegenerative Treatments
Korsana Biosciences Emerges from Stealth with $175 Millon in Funding to Advance Potential Best-in-Class Therapeutics for Neurodegenerative Diseases Korsana Biosciences, Inc. a biotechnology company discovering and developing novel therapies to…